Streetbeat News

Products Services

AMIX

Autonomix Medical announced promising preliminary results from its PoC trial for pancreatic cancer pain. The first five patients experienced significant pain relief with no major complications. The trial is on track to complete enrollment by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:03 pm

META

METD

METU

Direxion has launched two new ETFs, Direxion Daily META Bull 2X Shares (NASDAQ:METU) and Direxion Daily META Bear 1X Shares (NASDAQ:METD), to capitalize on Meta Platforms Inc's (NASDAQ:META) growth in AI and the metaverse. These ETFs are designed for short-term trading and require daily monitoring.

Portfolio Pulse from Surbhi Jain

June 18, 2024 | 12:02 pm

WKME

WalkMe has launched WalkMeX, an AI-driven copilot that provides contextual guidance for workflows across various applications, aiming to enhance digital adoption.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:01 pm

GENE

Genetic Technologies (GENE) is expanding its operations in North America, aiming to increase its market presence and enhance its service offerings in the region.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:01 pm

GOOG

GOOGL

Google's new FCC filing hints at a potential upgrade for the Nest Thermostat, featuring Wi-Fi, Bluetooth, and 60GHz radar. This could be a successor to the high-end Nest Learning Thermostat or a refresh of the entry-level model.

Portfolio Pulse from Ananya Gairola

June 18, 2024 | 11:52 am

MRK

Merck shares are trading higher after the FDA approved CAPVAXIVE for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:39 am

BBIO

BridgeBio Pharma has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 for Limb-girdle Muscular Dystrophy Type 2I/R9, with top-line results expected in 2025. The company is considering pursuing Accelerated Approval for BBP-418 following recent interactions with the FDA.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:36 am

PHIO

Phio Pharmaceuticals shares are trading higher after the company received a patent in South Korea for the INTASYL RXI-185 compound.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:36 am

ITCI

Intra-Cellular Therapies shares are trading higher after the company announced positive topline results from its second Phase 3 trial evaluating Lumateperone as adjunctive therapy for major depressive disorder, meeting primary and key secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:35 am

PHIO

Phio Pharmaceuticals has been granted a patent in South Korea for its Intasyl compound, which targets photo-aging in skin care.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 11:34 am